Corrections:
Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
Metrics: PDF 755 views | ?
1Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
3Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
4Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
5Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
6Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
*These authors contributed equally to this work
**Co-corresponding authors
Published: November 2, 2022
Copyright: © 2022 Gimotty et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has been corrected: Authors Kenneth S. Zaret and Erica L. Carpenter contributed equally as corresponding authors. The footnote to the author list indicating both individuals as co-corresponding authors was unintentionally omitted. The proper footnote is shown below:
** Co-corresponding authors
In addition, the paper’s title has been corrected to read, ‘THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.’ The authors declare that these corrections do not change the results or conclusions of this paper.
Original article: Oncotarget. 2021; 12:2266–2272. DOI: https://doi.org/10.18632/oncotarget.28099
![Creative Commons License](/images/80x15.png)
PII: 28127